Medications development for opioid abuse - sprookjes - yvandenbroek - TriplyDB

Medications development for opioid abuse

Medications development for opioid abuse

http://www.wikidata.org/entity/Q26853370

about

Agonist Medications for the Treatment of Cocaine Use Disorder Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis.Effects of 7-day continuous D-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys.Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.Utility of Nonhuman Primates in Substance Use Disorders Research.Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper.Attenuation of morphine withdrawal syndrome by various dosages of curcumin in comparison with clonidine in mouse: possible mechanism.

P2860

Q28087404-AAD22F2A-6FE6-4C3C-91F3-41A063B4CA81 Q34225896-E99C0BA9-D3E8-4FFC-9DE2-9336CC21F777 Q35027648-DB13D931-45D8-46E7-B599-191FBB6520FC Q35544688-7C39A06E-44AD-4E82-B604-8ABD2132D0FB Q36090475-D1F2F78C-353C-41FB-A650-4C9BDA636CCB Q38664308-06EEB7AF-5186-4B8E-B260-A08AF9BD27F3 Q38680773-51B83AA0-66D4-4E8A-98B0-BECD3FFFDEBD Q39034288-7688CA90-A5E5-4C9D-A939-6BA23B02D6CC Q41110701-B6E30E9E-CAF1-42E4-8115-E159118C0BD6 Q41883801-F0C8DA7D-A2CC-4E0B-9067-E940246051F4

P2860

Medications development for opioid abuse

http://www.wikidata.org/entity/Q26853370

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Medications development for opioid abuse

@ast

Medications development for opioid abuse

@en

Medications development for opioid abuse

@nl

type

label

Medications development for opioid abuse

@ast

Medications development for opioid abuse

@en

Medications development for opioid abuse

@nl

prefLabel

Medications development for opioid abuse

@ast

Medications development for opioid abuse

@en

Medications development for opioid abuse

@nl

P1433

Q26853370-0674B8F5-E06D-4334-9926-4214D764AD5B

P1476

Q26853370-EBA750BC-35DA-4BB8-8F41-355F394B8298

P2093

Q26853370-375ADAD0-17BC-4CCA-9135-2645131AF92E

Q26853370-9A0A378A-66F7-4A86-B9DA-1845685BF48C

P2860

Q26853370-00DCB95E-6344-4C15-BA59-78FDFDD4AEDB

Q26853370-06B3E4FE-CBE9-4E1B-94C4-065D4737529E

Q26853370-0B4A419E-FEBD-449B-9A36-CF4F0FB9C8B4

Q26853370-13082E88-8215-4FCB-86D1-4ED7EBCD06ED

Q26853370-18184BEA-7E47-4BC6-AC3E-19BDD79ACD18

Q26853370-1D468036-BF6F-43ED-B25F-DB456AD83858

Q26853370-20FDDEDF-470C-45AD-B0CA-80EAE5B6B8A5

Q26853370-34D15D60-742B-462B-B71F-9425C869998C

Q26853370-39198347-3009-457C-9749-DFA748298327

Q26853370-441BE8A0-FDAF-4F70-BFB6-B25D51D231F3

P304

Q26853370-F27D952E-0DA0-41E7-9599-62366C7F61D0

P31

Q26853370-9522DC4B-E13A-482D-99D6-6EFBD5D73542

P356

Q26853370-245C3599-AC03-41D5-AF39-411557158291

P407

Q26853370-D58AFD14-D00E-4C71-8A94-ED3E504EB604

P433

Q26853370-26696121-B0D4-4890-BDFF-10F1193527D1

P478

Q26853370-F00C5ABC-4524-46DE-B7C7-82649D03FD9A

P577

Q26853370-85063AAE-00CA-492B-8CD2-AC1C96899380

P5875

Q26853370-C9E7D88B-BCDA-4867-92AA-1C2B623FE801

P698

Q26853370-C2A354C1-BF37-4B96-8451-CCF813B02380

P921

Q26853370-1e01a412-b17e-490d-81da-3f3dc0594c24

P932

Q26853370-EA533907-A75D-4652-BB3B-A82F3C09AF24

P356

CSHPERSPECT.A012104

P1433

Cold Spring Harbor Perspectives in Medicine

P1476

Medications development for opioid abuse

@en

P2093

M. L. Banks

http://www.w3.org/2001/XMLSchema#string

S. S. Negus

http://www.w3.org/2001/XMLSchema#string

P2860

The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia

Evidence that opioids may have toll-like receptor 4 and MD-2 effects

Enzymatic pathways that regulate endocannabinoid signaling in the nervous system

Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.

Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.

The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse

Choice between food and heroin: effects of morphine, naloxone, and secobarbital.

Sustained-release naltrexone: novel treatment for opioid dependence.

Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strains

Principles of drug abuse liability assessment in laboratory animals.

P304

a012104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/CSHPERSPECT.A012104

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232813637

http://www.w3.org/2001/XMLSchema#string

P698

23125072

http://www.w3.org/2001/XMLSchema#string

P921

P932

3530034

http://www.w3.org/2001/XMLSchema#string